Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Advanz Pharma Corp (CXRXF)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
Advanz Pharma historical data, for real-time data please try another search
4.60 -0.41    -8.18%
15/01 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 3,326
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 4.00 - 4.60
Advanz Pharma 4.60 -0.41 -8.18%

Advanz Pharma Corp Company Profile

 
Get an in-depth profile of Advanz Pharma Corp, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

-

Equity Type

ORD

ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment’s products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company’s ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.

Contact Information

Address Capital House 85 King William Street
London, EC4N 7BL
United Kingdom
Phone 44 2085 889 100
Fax 44 2085 889 200
Web www.advanzpharma.com
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

ADVZ Comments

Write your thoughts about Advanz Pharma Corp
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Brian Holland
Brian Holland Mar 19, 2020 5:21PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Is this the company with the treatment that the President said they would use to compact the Coronavirus?
Reply
0 0
Report
Brian Ballarini
Brian Ballarini Mar 19, 2020 10:10AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
OPK to follow
Reply
0 0
Report
greg mason
greg mason Jan 28, 2020 12:06AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
take over in the wind? look at the valuation sweet if comes to fruitation...
Reply
0 0
Report
greg mason
greg mason Jan 25, 2020 3:37PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
instead of bailing out those big companies how bout bailing out the Bio companies which are finding medicines to help diseases in the world?
Reply
0 0
Report
greg mason
greg mason Jan 22, 2020 10:59PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Advanz set to do  very well in west Europe , just read fantastic report from private forum.. . always going to be lumps and bumps along the way, however my chart suggest and with some news could see an nice long to medium time frame investment. . . wonder if they will give dividends again with an nice yield?
Reply
0 0
Report
Monkey Monkey
TwoPennies Feb 08, 2017 1:45PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Institutional shorts r back i guess
Reply
0 0
Report
Monkey Monkey
TwoPennies Feb 08, 2017 10:03AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Today ninja trade day
Reply
0 0
Report
Dannii Thax
TraderThax Feb 07, 2017 2:03PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
why is this rising so? :D
Reply
0 0
Report
Monkey Monkey
TwoPennies Feb 03, 2017 8:28AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Bigly move up today ----> $5
Reply
0 0
Report
Monkey Monkey
TwoPennies Feb 02, 2017 4:11PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Seems to be in good shape now
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email